Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
American Journal of Hematology|November 26, 2013
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignanciesMark D Minden, Donna E Hogge, Scott J Weir, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood|May 28, 2009
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean-Luc Harousseau, Giovanni Martinelli, Wieslaw W Jedrzejczak, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Nature|February 14, 2014
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemiaLiran I Shlush, Sasan Zandi, Amanda Mitchell, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Leukemia|March 3, 2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trialRichard A Larson, Sumithra J Mandrekar, Lucas J Huebner, et al.
Pageof 6